Plos pathogens:以色列发现艾滋病治疗新途径

2018-06-27 佚名 科技部

以色列理工学院生物系研究人员最近发现猫科免疫缺陷病毒(FIV)逆转录酶的三维蛋白质结构,也因此揭示了抵抗这种病毒的机制,为进一步治疗抵抗艾滋病药物奠定了基础。该最新研究发现发表在近期出版的著名国际杂志《PLoS Pathogens》上。

以色列理工学院生物系研究人员最近发现猫科免疫缺陷病毒(FIV)逆转录酶的三维蛋白质结构,也因此揭示了抵抗这种病毒的机制,为进一步治疗抵抗艾滋病药物奠定了基础。该最新研究发现发表在近期出版的著名国际杂志《PLoS Pathogens》上。

研究发现,引发猫科动物免疫缺陷的病毒 FIV 和导致人类艾滋病的免疫缺陷病毒 HIV- 1 非常相似,它通过唾液转播病毒,使猫科动物免疫系统受损进而致病、发狂互咬,尤其对流浪猫比较常见。

研究者相信,由于 FIV 和 HIV- 1 存在很多相似,对 FIV 的研究发现将会帮助人们抵抗艾滋病,通过对其逆转录酶结构研究,可以开发药效更强、更专一的药物。这种药物能够抑制逆转录酶发挥作用,阻断病毒将 RNA 转成 DNA,使其不能复制,达到治疗艾滋病的效果。

原始出处:

Meytal Galilee, Akram Alian. The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance. Research Article | published 24 Jan 2018 PLOS Pathogens.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786124, encodeId=00281e86124a5, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Jan 02 10:37:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949423, encodeId=89dd194942360, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 25 05:37:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953378, encodeId=65a319533e817, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jan 22 08:37:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327484, encodeId=7ca132e484a0, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 27 17:21:50 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2019-01-02 cnxcy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786124, encodeId=00281e86124a5, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Jan 02 10:37:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949423, encodeId=89dd194942360, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 25 05:37:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953378, encodeId=65a319533e817, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jan 22 08:37:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327484, encodeId=7ca132e484a0, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 27 17:21:50 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786124, encodeId=00281e86124a5, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Jan 02 10:37:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949423, encodeId=89dd194942360, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 25 05:37:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953378, encodeId=65a319533e817, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jan 22 08:37:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327484, encodeId=7ca132e484a0, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 27 17:21:50 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786124, encodeId=00281e86124a5, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Jan 02 10:37:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949423, encodeId=89dd194942360, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun Nov 25 05:37:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953378, encodeId=65a319533e817, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jan 22 08:37:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327484, encodeId=7ca132e484a0, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 27 17:21:50 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-06-27 三生有幸9135

    学习一下

    0

相关资讯

英医疗史上很大丑闻!污染血源致***染艾滋 政府故意隐瞒 40 年

“红星新闻”微信公号 5 月 3 日消息,据 BBC 报道,英国最高法院本月将正式开启对英国国家医疗服务体系(NHS)历史上最大治疗丑闻的公开调查。从上世纪 80 年代起,英国有上千名血友病患者因接受治疗,感染丙型肝炎和艾滋病,最终痛苦地死去。

港大研究成果引关注 攻防艾滋病:它是矛又是盾

新药动物实验结果公布后,陈志伟的邮箱很快被淹没。来信的大都是HIV感染者,来自世界各地。有人心急火燎地咨询在哪儿才能买到新药,有人迫切希望成为临床试验的志愿者,有人甚至来到香港大学,冲进陈志伟的办公室。1.jpgBiIA-SG抗体结构及起效原理示意图媒体的反应同样强烈。许多报道称,陈志伟及合作者研发的新药或将“攻克艾滋”。外界的巨大关注源于令人振奋的实验结果:这种被命名为BiIA-SG的新型抗

J Periodontol: hla-b57.01可以指示艾滋病人的牙周健康?

本实验旨在评估患有慢性牙周炎的HIV感染者HLA-B57.01(人类白细胞抗原)与牙周临床参数之间的关系。

联合国官员:中国在终止艾滋病进程中扮演“重要角色”

联合国副秘书长兼联合国艾滋病规划署执行主任米歇尔·西迪贝12日在联合国总部表示,“中国在终止艾滋病进程中扮演重要角色”。

三十五年一无所获 艾滋病疫苗研发之路正确吗?

据国外媒体报道,20 世纪 80 年代末期,伯特? 多尔曼 (Burt Dorman) 准备退出疫苗接种领域。作为一名生物物理化学家,他花了数年时间成功经营一家制造动物疫苗的公司。这家公司开发出十几种针对猫科动物白血病和水疱性口炎等疾病的疫苗。随后多尔曼在一个新领域开创了一家致力于疾病诊断的新公司,致力于疾病诊断。

Sci Rep:基因“魔剪”成功灭活HIV基因 有望带来根治艾滋病的新疗法

日本神户大学近日宣布,该校龟冈正典准教授领导的研究小组利用基因“魔剪”CRISPR/Cas9编辑技术,开发出一种有效方法,能破坏艾滋病病毒(人类免疫缺陷病毒1型,HIV-1)的调节基因,成功抑制感染细胞内HIV-1的增殖。